Oct 15, 2026 03:30AM
Aug 6, 2026 08:00AM
May 13, 2026 04:01PM
Mar 10, 2026 04:01PM
Feb 2, 2026 08:01AM
Feb 2, 2026 08:00AM
Dec 18, 2025 04:05PM VTV Therapeutics submits phase 2 diabetes study protocol to UAE regulators
Dec 18, 2025 04:05PM
Nov 6, 2025 04:15PM
Oct 9, 2025 08:00AM
Oct 9, 2025 08:00AM
Sep 15, 2025 08:00AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
Aug 12, 2025 04:15PM
Aug 7, 2025 08:00AM
Aug 7, 2025 08:00AM
May 19, 2025 09:00AM
May 19, 2025 09:00AM
May 15, 2025 04:01PM
May 15, 2025 12:00PM vTv Therapeutics (VTVT) Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
May 15, 2025 12:00PM
Mar 20, 2025 05:35PM
Mar 17, 2025 08:30AM
Mar 17, 2025 08:30AM
Dec 2, 2024 04:05PM
Nov 12, 2024 04:05PM
Aug 8, 2024 04:15PM vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update
Jul 26, 2024 04:05PM
Jul 26, 2024 04:05PM
Jun 24, 2024 04:08PM
Jun 24, 2024 04:05PM
May 9, 2024 04:51PM
Mar 13, 2024 08:00AM
Mar 4, 2024 08:00AM vTv Therapeutics (VTVT) Announces FDA Submission for First Phase 3 Study of Cadisegliatin
Mar 4, 2024 08:00AM
Mar 1, 2024 08:00AM
Feb 28, 2024 08:01AM
Feb 28, 2024 08:00AM
Nov 9, 2023 04:30PM
Nov 8, 2023 08:00AM
Nov 2, 2023 08:05AM vTv Therapeutics (VTVT) Appoints Thomas Strack as Chief Medical Officer
Nov 2, 2023 08:00AM
Nov 1, 2023 08:01AM
Nov 1, 2023 08:00AM
Aug 11, 2023 04:31PM
Aug 11, 2023 04:30PM
Jun 16, 2023 08:03AM
Jun 16, 2023 08:00AM vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decli
May 24, 2023 09:03AM

1,202,303 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All